Cancer Family
Glandular Cell Neoplasm
CI-CAN-00000188Explore in graph →
Non-malignant2,823 active trials43 approved drugs426 evidence items
- NCIt
- C7132
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000188Explore in graph →
Clinical trials
10,205 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT05159440 | First in Human Study of TORL-2-307-MAB in Participants With Advanced Cancer | active not recruiting | Phase 1 | 70 | TORL Biotherapeutics, LLCINDUSTRY | 2 | Oct 22, 2024 | clinicaltrials |
| NCT05620134 | Study of JK08 in Patients with Unresectable Locally Advanced or Metastatic Cancer | active not recruiting | Phase 1 / Phase 2 | 263 | Salubris Biotherapeutics IncINDUSTRY | 2 | Oct 15, 2024 | clinicaltrials |
| NCT05215574 | Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 130 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | Oct 10, 2024 | clinicaltrials |
| NCT06632106 | HAIC in Combination with Immune Checkpoint Inhibitors and Tyrosine Kinase Inhibitors for Advanced HCC | active not recruiting | — | 97 | First Hospital of China Medical UniversityOTHER | 1 | Oct 8, 2024 | clinicaltrials |
| NCT04117945 | Regorafenib, With Cetuximab or Panitumumab, for the Treatment of Unresectable, Locally Advanced, or Metastatic Colorectal Cancer | active not recruiting | Phase 2 | 22 | Academic and Community Cancer Research UnitedOTHER | 1 | Sep 27, 2024 | clinicaltrials |
| NCT04970134 | Spanish Study for Molecular Characterization of Thyroid Carcinoma(MOLTHY) | active not recruiting | — | 150 | Grupo Español de Tratamiento de Tumores de Cabeza y CuelloOTHER | 1 | Sep 19, 2024 | clinicaltrials |
| NCT05022927 | A Phase I Study of ERY974 in Patients With Hepatocellular Carcinoma | active not recruiting | Phase 1 | 179 | Chugai PharmaceuticalINDUSTRY | 2 | Sep 5, 2024 | clinicaltrials |
| NCT01686126 | Improving the Treatment for Women With Early Stage Cancer of the Uterus(feMMe) | active not recruiting | Phase 2 | 165 | Queensland Centre for Gynaecological CancerOTHER_GOV | 2 | Aug 28, 2024 | clinicaltrials |
| NCT05710666 | Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) | active not recruiting | Phase 2 | 11 | Cancer Trials IrelandNETWORK | 1 | Aug 5, 2024 | clinicaltrials |
| NCT04554771 | Blood-borne Assessment of Stromal Activation in Esophageal Adenocarcinoma to Guide Tocilizumab Therapy(BASALT) | active not recruiting | Phase 2 | 41 | Academisch Medisch Centrum - Universiteit van Amsterdam (AMC-UvA)OTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06524466 | Neoadjuvant SBRT Combined With Lenvatinib and Pucotenlimab for Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 | 35 | Sun Yat-sen UniversityOTHER | 1 | Jul 29, 2024 | clinicaltrials |
| NCT06138769 | Lenvatinib After Progression on Atezolizumab-bevacizumab in Hepatocellular Carcinoma | active not recruiting | Phase 2 | 50 | Asan Medical CenterOTHER | 1 | Jul 3, 2024 | clinicaltrials |
| NCT02293980 | A Phase 1, Dose-Escalation Trial of PT2385 Tablets In Patients With Advanced Clear Cell Renal Cell Carcinoma (MK-3795-001) | active not recruiting | Phase 1 | 110 | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)INDUSTRY | 1 | Jun 17, 2024 | clinicaltrials |
| NCT04878783 | Radiomics and Molecular Expression Predictive Model for Esophago-Gastric Junction and Gastric Cancer TRG | active not recruiting | — | 138 | University of Roma La SapienzaOTHER | 2 | May 9, 2024 | clinicaltrials |
| NCT05982574 | Tumor Microenvironment | active not recruiting | — | 300 | University Hospital HeidelbergOTHER | 0 | May 8, 2024 | clinicaltrials |
| NCT06379334 | Discovering Urinary Protein Biomarkers for Hepatocellular Carcinoma in Chronic Hepatitis B Population | active not recruiting | — | 180 | Peking Union Medical College HospitalOTHER | 1 | Apr 23, 2024 | clinicaltrials |
| NCT02240836 | Energy Balance and Breast Cancer Aspects-II(EBBA-II) | active not recruiting | N/A | 545 | Oslo University HospitalOTHER | 1 | Apr 8, 2024 | clinicaltrials |
| NCT03281954 | Clinical Trial of Neoadjuvant Chemotherapy With Atezolizumab or Placebo in Patients With Triple-Negative Breast Cancer Followed After Surgery by Atezolizumab or Placebo | active not recruiting | Phase 3 | 1,550 | NSABP Foundation IncNETWORK | 2 | Apr 8, 2024 | clinicaltrials |
| NCT06271044 | a. Reducing Radioiodine Treatment in Papillary Thyroid Cancer. RAILESS | active not recruiting | N/A | 61 | Helsinki University Central HospitalOTHER | 0 | Feb 21, 2024 | clinicaltrials |
| NCT04909294 | Evaluation of the Efficacy and the Safety of a Stereotaxic Prostatic Radiotherapy Delivered With Linac MRI, in Patients With Prostate Adenocarcinoma(STEREO-RML) | active not recruiting | N/A | 68 | Centre Georges Francois LeclercOTHER | 1 | Feb 13, 2024 | clinicaltrials |
| NCT02641847 | TA(E)C-GP Versus A(E)C-T for the High Risk TNBC Patients and Validation of the mRNA-lncRNA Signature | active not recruiting | Phase 2 / Phase 3 | 503 | Fudan UniversityOTHER | 1 | Jan 25, 2024 | clinicaltrials |
| NCT05613283 | Primary Cervical Cancer Screening by Self-sampling HPV Test(PREVENT) | active not recruiting | — | 17,875 | Peking University People's HospitalOTHER | 1 | Dec 21, 2023 | clinicaltrials |
| NCT04045717 | Hypofractionated Focal Lesion Ablative Microboost in prostatE Cancer 2.0 | active not recruiting | Phase 2 | 124 | Universitaire Ziekenhuizen KU LeuvenOTHER | 2 | Dec 1, 2023 | clinicaltrials |
| NCT02407119 | Effects of H. Pylori Eradication on the Gastric Preneoplastic Lesion and Neoplasm After ESD | active not recruiting | Phase 3 | 470 | National Cancer Center, KoreaOTHER_GOV | 1 | Nov 9, 2023 | clinicaltrials |
| NCT06096896 | The Efficacy and Safety of EOB-MRI Guided Microwave Ablation for Early HCC: A Multicenter, Prospective, Observational Study | active not recruiting | — | 334 | Shandong Provincial HospitalOTHER_GOV | 1 | Oct 24, 2023 | clinicaltrials |
| NCT03501381 | High Dose IL 2 and Entinostat in RCC | active not recruiting | Phase 2 | 46 | Roberto PiliOTHER | 1 | Sep 1, 2023 | clinicaltrials |
| NCT02221999 | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients(SHPD002) | active not recruiting | Phase 2 / Phase 3 | 250 | RenJi HospitalOTHER | 1 | Aug 29, 2023 | clinicaltrials |
| NCT05433701 | Stereotactic Body Radiotherapy Versus Radiofrequency Ablation for Unresectable, Small (≤ 3 cm) HCC | active not recruiting | N/A | 178 | Jonggi ChoiOTHER | 1 | Aug 18, 2023 | clinicaltrials |
| NCT05955521 | Exosome as the Prognostic and Predictive Biomarker in EBC Patients | active not recruiting | N/A | 200 | Samsung Medical CenterOTHER | 1 | Jul 21, 2023 | clinicaltrials |
| NCT02889458 | Hong Kong Breast Cancer Study | active not recruiting | — | 7,000 | The University of Hong KongOTHER | 1 | May 23, 2023 | clinicaltrials |
| NCT03488667 | Perioperative mFOLFOX Plus Pembrolizumab in Gastroesophageal Junction (GEJ) and Stomach Adenocarcinoma | active not recruiting | Phase 2 | 40 | University of Kansas Medical CenterOTHER | 1 | May 19, 2023 | clinicaltrials |
| NCT02315196 | Pegylated Liposomal Doxorubicin Hydrochloride and Carboplatin Followed by Surgery and Paclitaxel in Treating Patients With Triple Negative Stage II-III Breast Cancer | active not recruiting | Phase 2 | 62 | Rutgers, The State University of New JerseyOTHER | 1 | Mar 29, 2023 | clinicaltrials |
| NCT04281667 | Mechanical Bowel Preparation and Oral Antibiotics Versus Mechanical Bowel Preparation Only Prior Rectal Surgery(MOBILE2) | active not recruiting | Phase 4 | 604 | Helsinki University Central HospitalOTHER | 1 | Nov 17, 2022 | clinicaltrials |
| NCT05190445 | Cinrebafusp Alfa in Combination With Ramucirumab and Paclitaxel in HER2-High Gastric or GEJ Adenocarcinoma and in Combination With Tucatinib in HER2-Low Gastric or GEJ Andenocarinoma | active not recruiting | Phase 2 | 80 | Pieris Pharmaceuticals, Inc.INDUSTRY | 2 | Sep 8, 2022 | clinicaltrials |
| NCT02938702 | Active Surveillance on Papillary Thyroid Microcarcinoma | active not recruiting | — | 1,211 | Seoul National University HospitalOTHER | 1 | Apr 25, 2022 | clinicaltrials |
| NCT03305146 | Feasibility of Molecular Biology in Pancreatic Cyst Tumors(CYST-GEN) | active not recruiting | N/A | 93 | Hospital St. Joseph, Marseille, FranceOTHER | 1 | Apr 14, 2022 | clinicaltrials |
| NCT03836352 | Study of an Immunotherapeutic, DPX-Survivac, in Combination With Low Dose Cyclophosphamide & Pembrolizumab, in Subjects With Selected Advanced & Recurrent Solid Tumors | active not recruiting | Phase 2 | 184 | ImmunoVaccine Technologies, Inc. (IMV Inc.)INDUSTRY | 2 | Mar 31, 2022 | clinicaltrials |
| NCT03308396 | Study of Durvalumab and Guadecitabine in Advanced Kidney Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | Ajjai Alva, MDOTHER | 1 | Feb 17, 2022 | clinicaltrials |
| NCT02493582 | The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR | active not recruiting | Phase 2 | 400 | The First People's Hospital of ChangzhouOTHER | 0 | Feb 5, 2016 | clinicaltrials |
Data updated 22 days agoSource updated Oct 22, 2024source: clinicaltrials